| Acute Ischemic Stroke Management | Lifetime | 34 | US 12 | 99.82 |
| Cerebrovascular and Carotid Artery Diseases | Lifetime | 52 | US 26 | 99.76 |
| Cardiovascular Health and Disease Prevention | Lifetime | 119 | US 60 | 99.27 |
| Long-Term Effects of COVID-19 | Lifetime | 159 | US 42 | 98.39 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 143 | US 70 | 99.23 |
| Blood Pressure and Hypertension Studies | Lifetime | 210 | US 96 | 99.28 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 125 | US 65 | 98.92 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 342 | US 146 | 99.11 |
| Cardiovascular Health and Risk Factors | Lifetime | 71 | US 44 | 98.74 |
| Lipoproteins and Cardiovascular Health | Lifetime | 231 | US 120 | 98.90 |
| Neuroinflammation and Neurodegeneration Mechanisms | Lifetime | 418 | US 188 | 98.59 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 748 | US 306 | 98.12 |
| Intracerebral and Subarachnoid Hemorrhage Research | Lifetime | 304 | US 131 | 97.73 |
| Cardiovascular and Diving-Related Complications | Lifetime | 226 | US 114 | 96.93 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 712 | US 293 | 97.71 |
| COVID-19 and healthcare impacts | Lifetime | 826 | US 294 | 92.60 |
| S100 Proteins and Annexins | Lifetime | 508 | US 234 | 95.44 |
| Cardiac Health and Mental Health | Lifetime | 723 | US 347 | 95.69 |
| Neurological Complications and Syndromes | Lifetime | 385 | US 150 | 94.16 |
| Moyamoya disease diagnosis and treatment | Lifetime | 527 | US 174 | 91.43 |
| Health, Environment, Cognitive Aging | Lifetime | 957 | US 468 | 89.94 |
| Aortic Thrombus and Embolism | Lifetime | 190 | US 82 | 86.55 |
| Acute Ischemic Stroke Management | 2021-2025 | 148 | US 43 | 98.69 |
| Cardiovascular Health and Risk Factors | 2021-2025 | 39 | US 28 | 97.41 |
| Cerebrovascular and Carotid Artery Diseases | 2021-2025 | 167 | US 60 | 97.78 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 134 | US 55 | 97.41 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 351 | US 95 | 97.55 |
| Cardiovascular and Diving-Related Complications | 2021-2025 | 47 | US 10 | 92.76 |
| Cardiovascular Health and Disease Prevention | 2021-2025 | 345 | US 100 | 90.35 |
| Cardiac Health and Mental Health | 2021-2025 | 784 | US 234 | 83.51 |
| Cerebral Venous Sinus Thrombosis | 2021-2025 | 711 | US 235 | 71.58 |
| Moyamoya disease diagnosis and treatment | 2021-2025 | 442 | US 105 | 72.60 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 521 | US 116 | 66.94 |
| Cerebrovascular and genetic disorders | 2021-2025 | 443 | US 75 | 51.82 |